CL2012000493A1 - Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. - Google Patents

Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.

Info

Publication number
CL2012000493A1
CL2012000493A1 CL2012000493A CL2012000493A CL2012000493A1 CL 2012000493 A1 CL2012000493 A1 CL 2012000493A1 CL 2012000493 A CL2012000493 A CL 2012000493A CL 2012000493 A CL2012000493 A CL 2012000493A CL 2012000493 A1 CL2012000493 A1 CL 2012000493A1
Authority
CL
Chile
Prior art keywords
benzylpiperazine
alkylamino
ketones
pyridine
procedure
Prior art date
Application number
CL2012000493A
Other languages
English (en)
Inventor
Sripathy Venkatraman
Syed Mahmood
Bingidimi I Mobele
Olga Lapina
Kellie Vercoe
Ying Li
Jonathan Salsbury
M Mclaws
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of CL2012000493A1 publication Critical patent/CL2012000493A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un método para sintetizar un compuesto derivado de piperazina disustituida con bencilo y ácido nicotínico, útiles para el tratamiento de condiciones neurológicas.
CL2012000493A 2009-08-24 2012-02-24 Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. CL2012000493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24

Publications (1)

Publication Number Publication Date
CL2012000493A1 true CL2012000493A1 (es) 2012-09-28

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000493A CL2012000493A1 (es) 2009-08-24 2012-02-24 Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.

Country Status (23)

Country Link
US (2) US9278933B2 (es)
EP (1) EP2470182B1 (es)
JP (1) JP5727482B2 (es)
KR (1) KR101701362B1 (es)
CN (2) CN105693601A (es)
AU (1) AU2010289802C1 (es)
BR (1) BR112012004161B1 (es)
CA (1) CA2772080C (es)
CL (1) CL2012000493A1 (es)
DK (1) DK2470182T3 (es)
ES (1) ES2475721T3 (es)
HK (1) HK1172844A1 (es)
HR (1) HRP20140621T1 (es)
IL (1) IL218298A (es)
IN (1) IN2012DN02370A (es)
MX (1) MX2012002335A (es)
NZ (1) NZ598891A (es)
PL (1) PL2470182T3 (es)
PT (1) PT2470182E (es)
RU (1) RU2567390C2 (es)
SG (1) SG178867A1 (es)
SI (1) SI2470182T1 (es)
WO (1) WO2011028548A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02370A (es) * 2009-08-24 2015-08-21 Neuralstem Inc
CN109952291B (zh) * 2016-09-12 2022-09-23 纽若斯丹公司 与糖尿病相关的神经缺陷的改善
WO2018075667A1 (en) * 2016-10-18 2018-04-26 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
WO2022140643A1 (en) * 2020-12-23 2022-06-30 Baylor College Of Medicine Small-molecule modulators of the orphan nuclear receptor tlx
JP2024520722A (ja) 2021-06-03 2024-05-24 オルト・ニューロサイエンス・インコーポレイテッド 不良な認知を有するうつ病患者の治療方法及びベンジルピペラジン－アミノピリジン剤の恩恵を受ける他の患者の選択
US20240197721A1 (en) 2022-12-05 2024-06-20 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2480481A1 (en) * 2002-03-29 2003-10-16 Schering Corporation Stereoselective alkylation of chiral 2-methyl-4-protected piperazines
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US20040185429A1 (en) * 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
JP4563386B2 (ja) * 2003-09-09 2010-10-13 エフ．ホフマン−ラ ロシュ アーゲー 精神病の処置のためのグリシン取り込み阻害剤としての１−（２−アミノ−ベンゾール）−ピペラジン誘導体
KR20070072562A (ko) * 2004-10-29 2007-07-04 반유 세이야꾸 가부시끼가이샤 오로라 ａ 선택적 억제 활성을 갖는 신규한 아미노피리딘유도체
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
RU2008129622A (ru) * 2005-12-20 2010-01-27 Новартис АГ (CH) Производные никотиновой кислоты в качестве модуляторов метаботропных глутаматных рецепторов
IN2012DN02370A (es) * 2009-08-24 2015-08-21 Neuralstem Inc

Also Published As

Publication number Publication date
US9278933B2 (en) 2016-03-08
RU2012111227A (ru) 2013-10-10
HK1172844A1 (en) 2013-05-03
PT2470182E (pt) 2014-07-24
WO2011028548A1 (en) 2011-03-10
RU2567390C2 (ru) 2015-11-10
KR20120054642A (ko) 2012-05-30
IL218298A0 (en) 2012-04-30
IL218298A (en) 2017-03-30
EP2470182A1 (en) 2012-07-04
EP2470182B1 (en) 2014-06-04
CA2772080C (en) 2017-05-30
US9481649B2 (en) 2016-11-01
JP5727482B2 (ja) 2015-06-03
SG178867A1 (en) 2012-04-27
AU2010289802C1 (en) 2015-04-16
MX2012002335A (es) 2012-07-04
IN2012DN02370A (es) 2015-08-21
US20160090358A1 (en) 2016-03-31
EP2470182A4 (en) 2013-04-24
AU2010289802A1 (en) 2012-04-12
SI2470182T1 (sl) 2014-10-30
NZ598891A (en) 2014-05-30
HRP20140621T1 (hr) 2014-11-21
ES2475721T3 (es) 2014-07-11
CN102711764A (zh) 2012-10-03
BR112012004161A2 (pt) 2016-03-29
AU2010289802B2 (en) 2014-10-02
DK2470182T3 (da) 2014-07-21
CN105693601A (zh) 2016-06-22
JP2013502462A (ja) 2013-01-24
BR112012004161B1 (pt) 2020-04-07
US20130005974A1 (en) 2013-01-03
CA2772080A1 (en) 2011-03-10
PL2470182T3 (pl) 2015-05-29
KR101701362B1 (ko) 2017-02-01

Similar Documents

Publication Publication Date Title
CL2012000493A1 (es) Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
TN2011000673A1 (en) Bace inhibitors
EA201170872A1 (ru) Ингибиторы протеинкиназы
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
TN2014000058A1 (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
GEP20135933B (en) Compounds as bradykinin b1 antagonists
TN2012000248A1 (en) Novel spiropiperidine compounds
UA104438C2 (uk) Спосіб одержання дабігатрану і його проміжних сполук
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
MY160392A (en) Triptolide prodrugs
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
BR112013016241A2 (pt) composto, e, método para fabricar um composto
WO2010102154A3 (en) Biaryl oxyacetic acid compounds
HK1124842A1 (en) Methods of preparing imidazole-based compounds
WO2010098583A2 (ko) 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
PH12016501704A1 (en) Method for producing 2-acyliminopyridine derivative
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
MX2012005733A (es) Metodo de produccion de derivados de acido glutamico marcados con f-18.
MY156873A (en) Novel forms of a multicyclic compound